Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Autor: Urbiola C; Division of Virology, Medical University of Innsbruck, Innsbruck, Austria.; Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria., Santer FR; Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria., Petersson M; Division of Virology, Medical University of Innsbruck, Innsbruck, Austria.; ViraTherapeutics GmbH, Innsbruck, Austria., van der Pluijm G; Department of Urology, Leiden University Medical Centre, Leiden, The Netherlands., Horninger W; Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria., Erlmann P; ViraTherapeutics GmbH, Innsbruck, Austria., Wollmann G; Division of Virology, Medical University of Innsbruck, Innsbruck, Austria.; Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria., Kimpel J; Division of Virology, Medical University of Innsbruck, Innsbruck, Austria., Culig Z; Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria., von Laer D; Division of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2018 Oct 01; Vol. 143 (7), pp. 1786-1796. Date of Electronic Publication: 2018 Jul 03.
DOI: 10.1002/ijc.31556
Abstrakt: Oncolytic viruses, including the oncolytic rhabdovirus VSV-GP tested here, selectively infect and kill cancer cells and are a promising new therapeutic modality. Our aim was to study the efficacy of VSV-GP, a vesicular stomatitis virus carrying the glycoprotein of lymphocytic choriomeningitis virus, against prostate cancer, for which current treatment options still fail to cure metastatic disease. VSV-GP was found to infect 6 of 7 prostate cancer cell lines with great efficacy. However, susceptibility was reduced in one cell line with low virus receptor expression and in 3 cell lines after interferon alpha treatment. Four cell lines had developed resistance to interferon type I at different levels of the interferon signaling pathway, resulting in a deficient antiviral response. In prostate cancer mouse models, long-term remission was achieved upon intratumoral and, remarkably, also upon intravenous treatment of subcutaneous tumors and bone metastases. These promising efficacy data demonstrate that treatment of prostate cancer with VSV-GP is feasible and safe in preclinical models and encourage further preclinical and clinical development of VSV-GP for systemic treatment of metastatic prostate cancer.
(© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
Databáze: MEDLINE
Externí odkaz: